Clinical Trial Update: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) [Phase 2]

View source ↗

Summary

Phase 2 perioperative trial evaluating Spartalizumab with the FLOT chemotherapy regimen for resectable gastric cancer; results were posted on 2026-04-14.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• DOCETAXEL (DOCETAXEL)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Spartalizumab (spartalizumab)

Snippet

Sponsor: Centre Francois Baclesse | Conditions: Gastric Cancer by AJCC V8 Stage, Resectable Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-04-14